Celltrion’s Truxima wins all the patent nullification trials in Korea
Celltrion announced the Intellectual Property Tribunal ruled nullification of the patent for the chronic lymphocytic leukemia(CLL) indication owned by Bio-Gen, which is related to the patent of Rituxan, the original product of Truxima, from the 7th of February.
Celltrion had anticipatively filed...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
